Chemotherapy Induced Nausea and Vomiting Pipeline

DelveInsight’s, “Chemotherapy Induced Nausea and Vomiting - Pipeline Insight, 2025” report provides comprehensive insights about 4+ companies and 6+ pipeline drugs in Chemotherapy Induced Nausea and Vomiting pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

Geography Covered

• Global coverage

 

Chemotherapy Induced Nausea and Vomiting: Understanding

Chemotherapy Induced Nausea and Vomiting: Overview

Chemotherapy-induced nausea and vomiting (CINV) remain among the most distressing and debilitating side effects of cancer treatment, often leading to significant declines in patients' quality of life, nutritional status, and treatment adherence. Although the introduction of advanced antiemetic regimens has substantially reduced the incidence of vomiting, nausea continues to affect 30–60% of patients, with many ranking it as one of the most severe treatment-related symptoms. CINV is influenced by a range of patient-specific factors, such as female sex, younger age, low alcohol intake, and a history of motion or morning sickness, as well as treatment-related variables like the type, dose, and schedule of chemotherapy. Agents are now classified by their emetogenic potential into four categories: highly, moderately, low, and minimally emetogenic. Furthermore, CINV is subdivided into acute, delayed, anticipatory, and breakthrough/refractory types, each with distinct timing and clinical implications. These complexities underscore the importance of individualized prevention and management strategies tailored to each patient’s risk profile and treatment plan.

 

The pathophysiology of chemotherapy-induced vomiting involves complex central nervous system pathways centered around the emetic center located in the brainstem's reticular formation. This center integrates input from three primary sources: the periphery, the cerebral cortex, and the chemoreceptor trigger zone (CTZ). Peripheral signals, often activated by gastrointestinal irritation from chemotherapy, are primarily mediated by serotonin (5-HT3) and neurokinin (NK) pathways. The cortical pathway, responsible for anticipatory nausea, involves neurotransmitters like dopamine and histamine. The CTZ, situated at the base of the brain and exposed to circulating toxins, detects emetogenic substances and communicates through all major neurochemical pathways. Once activated, the emetic center coordinates responses through the salivatory, vasomotor, respiratory, and cranial nerve centers, triggering the vomiting reflex via the diaphragm, abdominal muscles, stomach, and esophagus.

 

Nausea is a subjective, distressing sensation often described as a queasy or unsettled feeling that may or may not lead to vomiting. In contrast, vomiting is the physical expulsion of gastric contents through the mouth. While the two frequently occur together, they are distinct clinical phenomena. Nausea is commonly accompanied by symptoms such as tachycardia, excessive salivation, sweating, dizziness, pallor, light-headedness, anorexia, and general weakness, all of which can significantly impact a patient's well-being and daily functioning.

The management of chemotherapy-induced nausea and vomiting (CINV) has evolved significantly since the 1980s, with multiple classes of antiemetic agents now available that target various pathways involved in the emetic response. Key options include 5-HT3 receptor antagonists (e.g., ondansetron, granisetron, palonosetron), which block serotonin receptors in the gut and brain, and NK1 receptor antagonists (e.g., aprepitant, fosaprepitant), which inhibit substance P-mediated signaling. Corticosteroids, particularly dexamethasone, are frequently used in combination regimens to enhance efficacy for both acute and delayed CINV, despite not being FDA-approved specifically for this indication. Each agent class has a distinct mechanism of action and side effect profile, requiring individualized regimen selection based on treatment intensity, patient risk factors, and potential drug interactions. Guidelines from ASCO and NCCN provide frameworks for prophylaxis, but optimal management demands ongoing reassessment throughout the chemotherapy cycle to ensure efficacy and tolerability.

 

"Chemotherapy Induced Nausea and Vomiting- Pipeline Insight, 2025" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Chemotherapy Induced Nausea and Vomiting pipeline landscape is provided which includes the disease overview and Chemotherapy Induced Nausea and Vomiting treatment guidelines. The assessment part of the report embraces, in depth Chemotherapy Induced Nausea and Vomiting commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Chemotherapy Induced Nausea and Vomiting collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

 

Report Highlights

• The companies and academics are working to assess challenges and seek opportunities that could influence Chemotherapy Induced Nausea and Vomiting R&D. The therapies under development are focused on novel approaches to treat/improve Chemotherapy Induced Nausea and Vomiting.

 

Chemotherapy Induced Nausea and Vomiting Emerging Drugs Chapters

This segment of the Chemotherapy Induced Nausea and Vomiting report encloses its detailed analysis of various drugs in different stages of clinical development, including Phase III, II, I, Preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

 

Chemotherapy Induced Nausea and Vomiting Emerging Drugs

• RHB-102: RedHill Biopharma

RHB-102 is a patent-protected, proprietary, once-daily, bimodal extended-release, oral tablet formulation of the antiemetic drug ondansetron, a 5-HT3 antagonist, targeting potential indications including oncology support, acute gastroenteritis and gastritis, and IBS-D at two dose strengths, 12mg and 24mg.  RedHill Biopharma entered into an exclusive worldwide development and commercialization licensing agreement, excluding North America, with Hyloris Pharmaceuticals for RHB-102 for gastroenteritis & gastritis, IBS-D and oncology support. Currently, the drug is in Phase III stage of its development for the treatment of Chemotherapy Induced Nausea and Vomiting.

 

• APD403: Acacia Pharma

APD403 is based on the selective dopamine antagonist amisulpride, the same active ingredient as in Barhemsys®. It is being developed as an intravenous injection for cancer patients to be administered immediately before they receive chemotherapy to prevent acute CINV, and as an oral tablet to prevent delayed CINV. APD403 has successfully completed one proof-of-concept and one Phase II dose-ranging study demonstrating it is well tolerated and effective at preventing acute and delayed CINV. Currently, the drug is in Phase II stage of its development for the treatment of Chemotherapy Induced Nausea and Vomiting.

Further product details are provided in the report……..

 

Chemotherapy Induced Nausea and Vomiting: Therapeutic Assessment

This segment of the report provides insights about the different Chemotherapy Induced Nausea and Vomiting drugs segregated based on following parameters that define the scope of the report, such as:

Major  Players in Chemotherapy Induced Nausea and Vomiting

There are approx. 4+ key companies which are developing the therapies for Chemotherapy Induced Nausea and Vomiting. The companies which have their Chemotherapy Induced Nausea and Vomiting drug candidates in the most advanced stage, i.e. Phase III include, RedHill Biopharma.

 

Phases

DelveInsight’s report covers around 6+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

 

Route of Administration

Chemotherapy Induced Nausea and Vomiting pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Intravenous
• Subcutaneous
• Parenteral
• Topical

 

Molecule Type

Products have been categorized under various Molecule types such as

• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy

 

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

 

Chemotherapy Induced Nausea and Vomiting: Pipeline Development Activities

The report provides insights into different therapeutic candidates in Phase III, II, I, preclinical and discovery stage. It also analyses Chemotherapy Induced Nausea and Vomiting therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Chemotherapy Induced Nausea and Vomiting drugs.

 

Chemotherapy Induced Nausea and Vomiting Report Insights

• Chemotherapy Induced Nausea and Vomiting Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Chemotherapy Induced Nausea and Vomiting Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

 

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Chemotherapy Induced Nausea and Vomiting drugs?
• How many Chemotherapy Induced Nausea and Vomiting drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Chemotherapy Induced Nausea and Vomiting?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Chemotherapy Induced Nausea and Vomiting therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Chemotherapy Induced Nausea and Vomiting and their status?
• What are the key designations that have been granted to the emerging drugs?